The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …

Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last
years, particularly with the introduction of targeted therapies. Two groups of agents targeting …

There has been an intensive effort to develop novel therapies for the treatment of metastatic
colorectal cancer (mCRC). The anti‐epidermal growth factor receptor (EGFR) antibodies …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the advantages and disadvantages of the various chemotherapeutic regimens used to treat …

Background Colorectal cancer (CRC) is common in North America. Metastatic disease is
present at diagnosis in 30% of the patients, and approximately half of early-stage patients …

Colorectal cancer is a leading cause of cancer death worldwide. Recently the results of a
number of well-designed clinical trials conducted across the world have led to important …

Metastatic colorectal cancer is a significant cause of morbidity and mortality in the US and
around the world. While several novel cytotoxic and biologic therapies have been …

Great strides have been made in improving the outcome of patients with metastatic
colorectal cancer and targeted agents are an important part of the treatment arsenal. The …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the evolution of cancer chemotherapy for patients with colorectal cancer. Discuss …

Over the past 8 to 10 years, significant advances have been made in the treatment of
metastatic colorectal cancer (mCRC). In particular, the development of the targeted biologic …